Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Anthropic IPO Marketing Expected to Start in Mid-October 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
SEC Seeks ISS Client Voting Records in Proxy Adviser Probe 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Add as a preferred source on Google
AbbVie pharmaceutical company announced on Wednesday, Dec. 6, that it will buy Cerevel Therapeutics. This deal is the company's latest attempt to expand its drug pipeline, as its best-selling treatments are currently facing generic competition.
Share Prices Soar with the Buyout Deal
According to CNBC, the share prices of Cerevel Therapeutics shot up to 16% at the close on Wednesday. This is equivalent to almost $43 per share, just a little below the purchase price of over $8 billion.
On the other hand, AbbVie's were said to have slightly gone down by less than 1% in the extended trading. These changes in the share prices show that the acquisition negotiations between the companies have a slight effect on their value.
Agreed Terms of the Deal
AbbVie said that under the agreed terms of the transaction, it will buy all the outstanding shares of Cerevel Therapeutics for the price of $45.00 per share, which will be paid in cash. The deal values the neuroscience drugmaker at about $8.7 billion.
It was mentioned that the companies' respective boards of directors have already greenlighted the deal. This transaction is expected to be completed by mid-2024, subject to regulatory approvals, Cerevel shareholders' approval, and other customary closing conditions.
"Our existing neuroscience portfolio and our combined pipeline with Cerevel represents a significant growth opportunity well into the next decade," AbbVie's chairman and chief executive officer, Richard A. Gonzalez, said in a press release. "AbbVie will leverage its deep commercial capabilities, international infrastructure, and regulatory and clinical expertise to deliver substantial shareholder value with multibillion-dollar sales potential across Cerevel's portfolio of assets."
Ron Renaud, Crevel Therapeutics' president and chief executive officer, commented, "Cerevel has always been committed to transforming what is possible in neuroscience. With AbbVie's long-standing expertise in developing and commercializing medicines on a global scale, Cerevel's novel therapies will be well positioned to reach more people living with neuroscience diseases."
Photo by: Abbvie Media Resources
